RESUMEN
Conventional bolus calculators apply negative prandial corrections when premeal glucose levels are low. However, no study has evaluated the need for this negative correction with closed-loop systems. We analysed data retrospectively from a cohort study evaluating a closed-loop artificial pancreas system conducted in a diabetes camp over a period of 11 days. Meal boluses with negative correction (n = 98) of 47 participants aged 8 to 22 years were examined. If there was no insulin-on-board from previous boluses at mealtime, the postprandial hyperglycaemia rate increased with increased duration of insulin suspension (P = .03), with odds ratios being exaggerated by 17% per 10 minutes of suspension. However, if there was insulin-on-board from previous boluses, the hyperglycaemia rate did not change with increased duration of insulin suspension (P = .24). When there was no insulin-on-board, the rate of hyperglycaemia after meals preceded by no suspension was 21% (3/14), compared with 52% (12/23) and 64% (9/14) after meals preceded by suspensions of ≥50 and ≥70 minutes, respectively. Meal size did not influence these results. We conclude that, in the absence of insulin-on-board, negative prandial corrections may not be necessary following long insulin suspensions.
Asunto(s)
Diabetes Mellitus Tipo 1 , Hiperglucemia , Páncreas Artificial , Algoritmos , Glucemia , Estudios de Cohortes , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Humanos , Hiperglucemia/tratamiento farmacológico , Hiperglucemia/prevención & control , Hipoglucemiantes/uso terapéutico , Insulina/uso terapéutico , Sistemas de Infusión de Insulina , Periodo Posprandial , Estudios Retrospectivos , SuspensionesRESUMEN
BACKGROUND: Multiple daily injections (MDI) therapy for type 1 diabetes involves basal and bolus insulin doses. Non-optimal insulin doses contribute to the lack of satisfactory glycemic control. We aimed to evaluate the feasibility of an algorithm that optimizes daily basal and bolus doses using glucose monitoring systems for MDI therapy users. METHODS: We performed a pilot, non-inferiority, randomized, parallel study at a diabetes camp comparing basal-bolus insulin dose adjustments made by camp physicians (PA) and a learning algorithm (LA), in children and adolescents on MDI therapy. Participants wore a glucose sensor and underwent 11 days of daily dose adjustments in either arm. Algorithm adjustments were reviewed and approved by a physician. The last 7 days were examined for outcomes. RESULTS: Twenty-one youths (age 13.3 [SD, 3.7] years; 13 females; HbA1c 8.6% [SD, 1.8]) were randomized to either group (LA [n = 10] or PA [n = 11]). The algorithm made 293 adjustments with a 92% acceptance rate from the camp physicians. In the last 7 days, the time in target glucose (3.9-10 mmol/L) in LA (39.5%, SD, 20.7) was similar to PA (38.4%, SD, 15.6) (P = .89). The number of hypoglycemic events per day in LA (0.3, IQR, [0.1-0.6]) was similar to PA (0.2, IQR, [0.0-0.4]) (P = .42). There was no incidence of severe hypoglycemia nor ketoacidosis. CONCLUSIONS: In this pilot study, glycemic outcomes in the LA group were similar to the PA group. This algorithm has the potential to facilitate MDI therapy, and longer and larger studies are warranted.
Asunto(s)
Algoritmos , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Cálculo de Dosificación de Drogas , Insulina/administración & dosificación , Adolescente , Automatización , Glucemia/análisis , Glucemia/metabolismo , Automonitorización de la Glucosa Sanguínea/instrumentación , Niño , Diabetes Mellitus Tipo 1/sangre , Esquema de Medicación , Estudios de Equivalencia como Asunto , Estudios de Factibilidad , Femenino , Humanos , Inyecciones Subcutáneas , Sistemas de Infusión de Insulina , Masculino , Proyectos Piloto , Quebec , Resultado del TratamientoRESUMEN
Background: Optimizing programmed basal rates and carbohydrate ratios may improve the performance of the artificial pancreas. We tested, in a diabetes camp, the efficacy of a learning algorithm that updates daily basal rates and carbohydrate ratios in the artificial pancreas. Materials and Methods: We conducted a randomized crossover trial in campers and counselors aged 8-21 years with type 1 diabetes on pump therapy. Participants underwent 2 days of artificial pancreas alone and 6 days of artificial pancreas with learning. During the artificial pancreas with learning, programmed basal rates and carbohydrate ratios were updated daily based on the learning algorithm's recommendations. All algorithm recommendations were reviewed for safety by camp physicians. The primary outcome was the time in target range (3.9-10 mmol/L) of the last 2 days of each intervention. Results: Thirty-four campers (age 13.9 ± 3.9, hemoglobin A1c 8.3% ± 0.2%) were included. Ninety-six percent of algorithm recommendations were approved by the camp physicians. Participants were in closed-loop mode 74% of the time. There was no difference between interventions in time in target (55%-55%; P = 0.71) nor in hypoglycemia events (0.8-0.9 events per day; P = 0.63). This was despite changes in programmed basal rate ranging from -21% to +117%, and changes in breakfast, lunch, and supper carbohydrate ratios from -17% to +40%, -36% to +37%, and -35% to +63%, respectively. Morever, postprandial hyperglycemia and hypoglycemia did not decrease in participants whose carbohydrate ratios were decreased (more insulin boluses) and increased (less insulin boluses), respectively. Conclusions: In camp settings, despite adjustments to programmed basal rates and carbohydrate ratios, the learning algorithm did not change glycemia, which may point toward limited effect of these adjustments in environments with large day-to-day variability in insulin needs. Longer randomized studies in real-world settings are required to further assess the efficacy of automatic adjustments of programmed basal rates and carbohydrate ratios.
Asunto(s)
Automonitorización de la Glucosa Sanguínea/instrumentación , Glucemia/análisis , Diabetes Mellitus Tipo 1/sangre , Carbohidratos de la Dieta/análisis , Sistemas de Infusión de Insulina , Páncreas Artificial , Adolescente , Algoritmos , Metabolismo Basal , Niño , Estudios Cruzados , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Femenino , Hemoglobina Glucada/análisis , Humanos , Hiperglucemia/inducido químicamente , Hipoglucemia/inducido químicamente , Hipoglucemiantes/administración & dosificación , Insulina/administración & dosificación , Masculino , Comidas , Resultado del Tratamiento , Adulto JovenRESUMEN
Adrenal suppression (AS) is an important side effect of glucocorticoids (GCs) including inhaled corticosteroids (ICS). AS can often be asymptomatic or associated with non-specific symptoms until a physiological stress such as an illness precipitates an adrenal crisis. Morbidity and death associated with adrenal crisis is preventable but continues to be reported in children. There is a lack of consensus about the management of children at risk of AS. However, healthcare professionals need to develop an awareness and approach to keep these children safe. In this article, current knowledge of the risk factors, diagnosis and management of AS are reviewed while drawing attention to knowledge gaps and areas of controversy. Possible strategies to reduce the morbidity associated with this iatrogenic condition are provided for healthcare professionals.
Asunto(s)
Corticoesteroides/efectos adversos , Glándulas Suprarrenales/efectos de los fármacos , Androstadienos/efectos adversos , Antiasmáticos/efectos adversos , Asma/tratamiento farmacológico , Broncodilatadores/efectos adversos , Síndrome de Cushing/inducido químicamente , Administración por Inhalación , Corticoesteroides/administración & dosificación , Glándulas Suprarrenales/metabolismo , Hormona Adrenocorticotrópica/sangre , Androstadienos/administración & dosificación , Antiasmáticos/administración & dosificación , Biomarcadores/sangre , Broncodilatadores/administración & dosificación , Síndrome de Cushing/sangre , Esquema de Medicación , Femenino , Fluticasona , Humanos , Hidrocortisona/sangre , Persona de Mediana EdadRESUMEN
Hypothalamic hamartomas (HHs) are tumors generally associated with isolated central precocious puberty (CPP). To our knowledge, we report a unique case of a girl with HH associated with CPP and growth hormone deficiency. This case highlights the complex interaction between HHs and the hypothalamic-pituitary-gonadal axis. It also emphasizes the value of close follow-up of growth velocity in these patients even after treatment of the CPP.
Asunto(s)
Hormona del Crecimiento/deficiencia , Hamartoma/complicaciones , Enfermedades Hipotalámicas/complicaciones , Pubertad Precoz/etiología , Adolescente , Femenino , HumanosRESUMEN
Systemic corticosteroids play an integral role in the management of many inflammatory and immunologic conditions, but these agents are also associated with serious risks. Osteoporosis, adrenal suppression, hyperglycemia, dyslipidemia, cardiovascular disease, Cushing's syndrome, psychiatric disturbances and immunosuppression are among the more serious side effects noted with systemic corticosteroid therapy, particularly when used at high doses for prolonged periods. This comprehensive article reviews these adverse events and provides practical recommendations for their prevention and management based on both current literature and the clinical experience of the authors.
RESUMEN
BACKGROUND: Cystic fibrosis (CF) is characterized by chronic inflammation with increased oxidative stress. We evaluated the relationship between glucose tolerance and oxidative stress in CF children. METHODS: Patients 10-18 years old underwent oral glucose tolerance testing (n=31). At 2-h, we assessed blood glutathione and 4-hydroxynonenal-protein adducts (HNE-P), and urine 1,4-dihydroxynonane-mercapturic acid conjugate (DHN-MA). Plasma fatty acid (FA) profile was performed. Patients with impaired glucose tolerance (IGT) were retested 6 to 24 months later and received additional nutritional recommendations (NR) when possible. RESULTS: Fifty-two percent of patients had normal glucose tolerance (NGT), 42% IGT and 6% cystic fibrosis-related diabetes (CFRD). HNE-P concentrations significantly increased with diabetes (109%). Two-h BG correlated positively with HNE-P and negatively with DHN-MA. FA profile was modified with IGT. Of retested IGT patients, 25% received no NR; they remained IGT at 6 months and progressed to CFRD. Of those who received NR, 67% normalized, 11% remained intolerant and 22% developed CFRD. HNE-P levels dropped (88%) in IGT patients reverting to NGT, increased (94%) in the IGT patients with NR developing CFRD, decreased (90%) with persistent IGT. CONCLUSION: CF children showed evidence of increased oxidative stress with worsening of glucose metabolism. NR may delay the appearance of CFRD.
Asunto(s)
Fibrosis Quística/complicaciones , Diabetes Mellitus/etiología , Intolerancia a la Glucosa/diagnóstico , Intolerancia a la Glucosa/etiología , Estrés Oxidativo , Acetilcisteína/análogos & derivados , Acetilcisteína/orina , Adolescente , Análisis de Varianza , Niño , Fibrosis Quística/fisiopatología , Ácidos Grasos/sangre , Femenino , Prueba de Tolerancia a la Glucosa , Glutatión/sangre , Humanos , Masculino , Proteínas de la Membrana/sangre , Proyectos Piloto , Pruebas de Función RespiratoriaRESUMEN
We report three pediatric cases of primary hypothyroidism presenting with musculoskeletal complaints, elevated muscle enzymes and increased creatinine. Thyroid hormone replacement led to improvement in both the clinical features and laboratory abnormalities.
Asunto(s)
Creatinina/metabolismo , Hipotiroidismo/diagnóstico , Polimiositis/diagnóstico , Niño , Diagnóstico Diferencial , Femenino , Humanos , Hipotiroidismo/complicaciones , Hipotiroidismo/metabolismo , Masculino , Polimiositis/complicaciones , Polimiositis/metabolismo , Síndrome , Pruebas de Función de la TiroidesRESUMEN
A 13-year-old girl with obesity and hyperinsulinism developed steroid-resistant nephrotic syndrome due to collapsing glomerulopathy with dominant C1q-containing mesangial immune deposits (CG/C1qN). She became overtly diabetic while receiving alternate-day prednisone and tacrolimus, requiring insulin injections. Despite the addition of mycophenolate mofetil to the treatment regimen, renal function subsequently declined. Rituximab (four weekly doses of 375 mg/m2) was tried 6 months after initial presentation and 3 months after weaning all glucocorticoids. Glomerular filtration rate (GFR) and proteinuria improved. Unexpectedly, blood sugar control normalized 6 weeks after antibody infusion. Rituximab was readministered 20 months after the first course because of deteriorating renal function, but the effect on GFR and proteinuria was modest. A retrospective analysis revealed that tubulointerstitial infiltrates present in the biopsies prior to treatment with rituximab contained numerous CD20+ and CD3+ (CD4 > CD8) lymphocyte aggregates. Rebiopsy 10 weeks after repeat rituximab therapy demonstrated the elimination of B-cell infiltrates and the apparent decrease of interstitial T-cell infiltrates, yet persistent, advanced global glomerulosclerosis, interstitial fibrosis and tubular atrophy. In conclusion, CG/C1qN was associated with B- and T-cell-rich tubulointerstitial infiltrates. B-cell-directed therapy delayed clinical progression during early disease but failed to prevent or ameliorate chronic changes, despite effective tissue B-cell clearance. The incidental resolution of diabetes was noted after rituximab treatment.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Complemento C1q/inmunología , Glomerulonefritis , Factores Inmunológicos/administración & dosificación , Síndrome Nefrótico , Adolescente , Anticuerpos Monoclonales de Origen Murino , Biopsia , Relación CD4-CD8 , Complemento C1q/metabolismo , Quimioterapia Combinada , Femenino , Glomerulonefritis/tratamiento farmacológico , Glomerulonefritis/inmunología , Glomerulonefritis/patología , Glucocorticoides/administración & dosificación , Humanos , Inmunosupresores/administración & dosificación , Glomérulos Renales/inmunología , Glomérulos Renales/metabolismo , Glomérulos Renales/patología , Síndrome Nefrótico/tratamiento farmacológico , Síndrome Nefrótico/inmunología , Síndrome Nefrótico/patología , Prednisona/administración & dosificación , Rituximab , Tacrolimus/administración & dosificaciónRESUMEN
We report a case of bone pain associated with primary hyperparathyroidism in a patient with sickle cell disease. A 17-year-old girl with sickle cell disease (SS phenotype) was seen for bilateral knee and back pain. She had had recurrent severe vaso-occlusive crises and acute chest syndrome in the course of her disease. In the last 2 years, she had frequent visits to the emergency department for severe bone pain. She complained of long-standing fatigue and lethargy. Her physical examination was normal. Hydroxyurea treatment, as well as and long- and short-acting narcotics were given, with little improvement in symptoms. Poor compliance with medication, family dysfunction, and potential narcotic addiction were felt to be significant contributors to the patient's symptoms. She was incidentally found to have an extremely elevated total calcium level of 3.19 mmol/L (range: 2.25-2.76) with an ionized calcium level of 1.9 mmol/L (range: 1.15-1.35). Phosphorus level was 0.82 mmol/L (range: 0.90-1.50), alkaline phosphatase level was elevated at 519 U/L (range: 10-170), and parathyroid hormone level was extremely high at 1645 pg/mL (range: 10-60). Her renal function was normal. Ultrasonography of the neck and a Sestamibi scan revealed a single left inferior parathyroid adenoma adjacent to the thyroid lobe. There was no evidence of an underlying multiple endocrine neoplasia. The patient was diagnosed with primary hyperparathyroidism. Fluid hydration, hydrocortisone, calcitonin, and bisphosphonates were initiated for acute hypercalcemia management before surgical excision of the left parathyroid adenoma. On review of previous blood work, a borderline calcium level of 2.72 was present 18 months before this admission. Two years postsurgery, she has normal renal function, calcium, and parathyroid hormone levels. The weekly visits to the emergency department for pain episodes decreased to 1 every 2 months within the first few months after her surgery. The decrease in pain episodes, even if it coincided with the treatment of primary hyperparathyroidism, may still reflect the natural evolution of sickle cell disease in this patient. However, the high morbidity associated with primary hyperparathyroidism was successfully prevented in this patient. Primary hyperparathyroidism is rare in childhood. In a recent study, it occurred more commonly in female adolescents and was because of a single adenoma, as in our patient. Significant morbidity, mainly secondary to renal dysfunction, was because of the delay in diagnosis after the onset of symptoms (2.0-4.2 years), emphasizing the need for a rapid diagnosis. Sickle cell disease affects approximately 1 of every 600 blacks in North America. Acute episodes of severe vaso-occlusive crisis account for > 90% of sickle cell-related hospitalizations and are a significant cause of morbidity in patients. There is no known association between sickle cell disease and primary hyperparathyroidism, and this case is most probably a random occurrence. However, as emphasized by this case report, pain may also be a harbinger of other disease processes in sickle cell disease. Because management may vary, we suggest that care providers consider the diagnosis of vaso-occlusive crisis as the diagnosis of exclusion and that other etiologies for pain be envisaged in this patient population, especially in the presence of prolonged pain or unusual clinical, radiologic, or biological findings.
Asunto(s)
Adenoma/complicaciones , Anemia de Células Falciformes/complicaciones , Artralgia/etiología , Dolor de Espalda/etiología , Hiperparatiroidismo/diagnóstico , Articulación de la Rodilla , Neoplasias de las Paratiroides/complicaciones , Enfermedades Vasculares/diagnóstico , Adenoma/diagnóstico , Adolescente , Analgésicos Opioides/uso terapéutico , Anemia de Células Falciformes/tratamiento farmacológico , Resorción Ósea/etiología , Diagnóstico Diferencial , Servicio de Urgencia en Hospital , Femenino , Humanos , Hidroxiurea/uso terapéutico , Hipercalcemia/etiología , Hiperparatiroidismo/sangre , Hiperparatiroidismo/etiología , Hormona Paratiroidea/sangre , Neoplasias de las Paratiroides/diagnóstico , Recurrencia , Negativa del Paciente al Tratamiento , Enfermedades Vasculares/etiologíaRESUMEN
OBJECTIVES: To determine lumbar spine and total body bone mineral density (BMD) in pediatric patients who have undergone cranial or craniospinal irradiation for posterior fossa tumors, specifically medulloblastoma and ependymoma and to analyze the association between degree of osteopenia and factors that may affect BMD. METHODS: Retrospective and prospective data collection included medical record review and examination, including pubertal, dietary, and activity assessment. Lumbar spine and total body BMD were measured by means of dual energy x-ray absorptiometry. Patients were routinely observed by the endocrinology department, and hormone deficiencies were corrected promptly. A subset of patients received calcium and vitamin D supplementation and underwent repeat BMD measurement 1 year later. RESULTS: Of 24 patients aged 4 to 20 years, 11 of whom were male, recruited from 1996 through 1999, 19 had medulloblastoma. All 19 underwent craniospinal radiotherapy plus a boost to the posterior fossa (mean +/- SD of 5410 +/- 130 rad [54.1 +/- 1.3 Gy] to the posterior fossa, mean +/- SD of 3470 +/- 460 rad [34.7 +/- 4.6 Gy] to the whole brain and spinal axis), and 8 of 19 underwent chemotherapy. The remaining 5 patients had ependymoma and underwent irradiation to the posterior fossa only (mean +/- SD of 5680 +/- 720 rad [56.8 +/- 7.2 Gy]). Therefore, there were 3 treatment groups: craniospinal irradiation and chemotherapy, only craniospinal irradiation, and only posterior fossa irradiation. Bone mineral studies were performed a mean +/- SD of 5.42 +/- 3.23 years after therapy. Our patients had lower total body BMD (mean z score, -0.47; 95% confidence interval, -0.85 to -0.09) and lumbar spine BMD (mean z score, -1.27; 95% confidence interval, -1.81 to -0.73) as compared with those of the the general population. There was no significant difference in mean lumbar spine BMD between patients in the 3 groups. Our patients consumed a diet deficient in vitamin D and calcium (mean +/- SD 53.6% +/- 24.1% and 70.0% +/- 37.4% of the amount recommended, respectively). Of 7 patients who underwent measurements 1 year later, 5 had in increase in BMD that was parallel to normal curves, with no compensatory increase. Four patients were hypothyroid, 6 were growth hormone deficient, and 6 were both. All hormones were replaced, with the exception of growth hormone in 1 patient. By using regression analysis, the factors that affected lumbar spine BMD, protectively in both cases, were calcium intake (beta = 0.015, 95% confidence interval, 0.001-0.029) and female sex (beta = 1.422, 95% confidence interval, 0.456-2.388). CONCLUSIONS: Children who have undergone irradiation for posterior fossa tumors have diminished total body and lumbar spine BMD, as compared with those of the general population. This reduction was similar within all 3 treatment groups, which suggests that chemotherapy did not play a major role and that localized irradiation may have systemic effects. This population often has balance and gait problems, so the risk of falling, coupled with osteopenia, may place them at considerably increased risk of fractures.
Asunto(s)
Densidad Ósea/efectos de la radiación , Enfermedades Óseas Metabólicas/etiología , Ependimoma/radioterapia , Neoplasias Infratentoriales/radioterapia , Meduloblastoma/radioterapia , Adolescente , Adulto , Enfermedades Óseas Metabólicas/epidemiología , Niño , Preescolar , Ependimoma/epidemiología , Femenino , Humanos , Masculino , Análisis Multivariante , Estado Nutricional , Estudios Prospectivos , Radioterapia/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Columna Vertebral/efectos de la radiaciónRESUMEN
OBJECTIVE: The purpose of this study was to determine the obstetric and neonatal outcomes of women with prepregnancy diagnoses of epilepsy. STUDY DESIGN: This was a cohort study of women with epilepsy (n=414 women) who were delivered in a tertiary referral center (1978-2000). Outcomes were compared with women who did not have epilepsy (n=81,759 women) who were delivered during the same period, with the use of t tests or contingency table analyses. RESULTS: Comparison showed increased rates of nonproteinuric hypertension (P<.05), induction of labor (P<.001), and fetal cardiovascular malformations (P<.001) among women with epilepsy. Rates of other antenatal, intrapartum, and neonatal complications and congenital malformations were similar to those of control subjects. There were fewer instrumental vaginal deliveries. There were no live births with neural tube defects. The occurrence of major antepartum seizures did not increase the rate of adverse outcomes significantly. Major congenital malformations increased in proportion to the number of anticonvulsants that were prescribed. CONCLUSION: Women with epilepsy are not at increased risk for obstetric complications, provided that appropriate care is available during preconception, pregnancy, labor, delivery, and after delivery.